InsiderSignal.AI

InsiderSignal.ai

PCVX - Vaxcyte, Inc.

Insider Sale by Wassil Jim (COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Wassil Jim, serving as COO at Vaxcyte, Inc. (PCVX), sold 2,250 shares at $56.83 per share, for a total transaction value of $127,870.00. Following this transaction, Wassil Jim now holds 160,744 shares of PCVX.

This sale represents a 1.00% decrease in Wassil Jim's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, May 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 1, 2026, meaning the disclosure happened on the same day as the trade.

Vaxcyte, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Wassil Jim

Wassil Jim

COO

Jim Wassil (age 55) is the Executive Vice President and Chief Operating Officer at Vaxcyte, Inc. (PCVX), serving as COO since December 2019 and elevated to EVP in March 2022.[[1]](https://fintool.com/app/research/companies/PCVX/people/jim-wassil)[[2]](https://www.marketscreener.com/insider/JAMES-WASSIL-A2X66S/)[[4]](https://vaxcyte.com/about-us/) He brings over three decades of experience in vaccine development and commercialization, with prior senior leadership roles at Pfizer (Vice President & Global Health and Value Business Unit Lead, Vaccines, 2015–2019, overseeing market access and portfolio including Prevnar), Novartis (Head of Global Product Development and U.S. Marketing for meningococcal vaccines, 2008–2015, leading launches of Menveo and Bexsero), and Merck (Senior Director of International Marketing for pediatric vaccines, 1992–2008, launching RotaTeq, plus technical roles in research, quality, and regulatory).[[1]](https://fintool.com/app/research/companies/PCVX/people/jim-wassil)[[3]](https://health.lehigh.edu/faculty/wassil-jim)[[4]](https://vaxcyte.com/about-us/) Wassil holds a B.S. in Chemistry/Biology from the University of Notre Dame, an M.S. in Bioorganic Chemistry, and an MBA from Lehigh University.[[1]](https://fintool.com/app/research/companies/PCVX/people/jim-wassil)[[3]](https://health.lehigh.edu/faculty/wassil-jim)[[4]](https://vaxcyte.com/about-us/) His accolades include the 2014 VIVA Award from Novartis for Bexsero approval and being an ACE Finalist for RotaTeq studies in Nicaragua.[[4]](https://vaxcyte.com/about-us/) Previously, he served as a Director at Icosavax, Inc. (2022–2024) until its acquisition by AstraZeneca, and is a member of the Infectious Diseases Society of America.[[1]](https://fintool.com/app/research/companies/PCVX/people/jim-wassil)[[2]](https://www.marketscreener.com/insider/JAMES-WASSIL-A2X66S/)

View full insider profile →

Trade Price

$56.83

Quantity

2,250

Total Value

$127,870.00

Shares Owned

160,744

Trade Date

Friday, May 1, 2026

4 days ago

SEC Filing Date

Friday, May 1, 2026

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning PCVX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6109854

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime